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ABSTRACT 
The etiology of rheumatoid arthritis (RA) remains unknown; however, there is a preclinical 
period of RA development during which autoimmunity is present in the absence of inflammatory 
arthritis supporting that autoimmunity in RA originates at a site outside of the joints. The hypothesis 
of these studies is that the lung mucosa is an originating site of anti-citrullinated protein/peptide 
antibodies (ACPA) in RA. Using induced sputum, we demonstrate that sputum ACPA is strongly 
associated with classifiable RA. Importantly, sputum ACPA, particularly ACPA-IgA, was also 
present in the lung in a portion of subjects who are At-Risk for developing RA in the future, and 
many of these sputum ACPAs in At-Risk subjects appear to be generated in the lung. Furthermore, 
levels of sputum ACPA were correlated with sputum neutrophils and macrophages supporting that 
sputum ACPAs are associated with local airway inflammation. In longitudinal studies, At-Risk and 
RA subjects were more likely than Controls to develop incident sputum ACPA positivity. However, a 
portion of At-Risk and RA subjects also had resolution of sputum ACPA positivity over time. As 
such, there was not an overall demonstration of increasing sputum ACPA positivity overtime, which 
may be a reflection of natural fluctuations in IgA related autoantibodies. Lastly, using a unique cohort 
of subjects with lung tissue available, we identified associations between serum ACPA, particularly 
ACPA-IgA, and the presence of inducible bronchus associated lymphoid tissue like structures in the 
lung that could represent a mechanism by with ACPA is generated locally in the lung. Overall, these 
findings support the hypothesis that the lung is a mucosal site of ACPA generation in a portion of 
subjects who are At-Risk for developing RA, although other mucosal sites also likely contribute to 
ACPA generation in some individuals. These findings also support that ACPA generation in the lung 
could be transient, and it will be important in future studies to address whether ACPA generation in
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the lung is part of a natural localized autoimmunity as well as what mechanisms contribute to the 
persistent generation of ACPA in the lung as well as transitions from mucosal to systemic 
autoimmunity and ultimately inflammatory arthritis.    
The form and content of this abstract are approved. I recommend its publication. 
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Rheumatoid arthritis (RA) is a systemic autoimmune disease for which the etiology is 
unknown. Established data support that disease specific autoantibodies, including antibodies to 
citrullinated protein/peptide antigens (ACPA), may be initially generated at a mucosal site such as the 
lung. However, in order to study the early generation of ACPA in RA, studies must include 
individuals who are in a preclinical period of RA development. Such individuals can be considered 
‘At-Risk’ for the future development of RA and are highly informative to understanding the early 
phases of autoimmunity in RA. The purpose of this project is to investigate the lung as an originating 
mucosal site of ACPA generation in RA through the cross-sectional and longitudinal evaluation of 
induced sputum in subjects At-Risk for RA as well as the evaluation of lung tissue histology. Our 
hypothesis is that an inhaled factor interacts with the immune system at the airway mucosa triggering 
inflammation and ACPA generation that is initially localized to the lung. Over time, this localized 
autoimmunity can become systemic through cellular activation in regional lymph nodes, and 
ultimately, after years of preclinical systemic autoimmunity, an individual can develop inflammatory 
arthritis that is classifiable as RA.  
Because it is currently unknown where RA-related autoimmunity initially develops, it is 
unclear how best to study the specific mechanisms that lead to loss of tolerance and generation of 
autoimmunity in RA. Determining the lung as an initiating site of ACPA in RA will support future 
studies that focus on the lung as well as other mucosal sites in order to identify the etiology of RA. 
Importantly, such future studies can lead to site-specific and mechanism-specific targeted therapies 








The overall purpose of this project is to investigate the lung as an originating mucosal site of 




The research questions in this project include: 1) Are ACPA generated in the lung in the 
preclinical period of RA and/or the period of RA after arthritis onset? 2) Are ACPA present in the 
lung in individuals who are negative for that antibody in the blood supporting the lung as an 
originating site of these antibodies? 3) Does incident ACPA develop in the lung over time? and 4) 
Are ectopic lymphoid tissues present in the lung in association with ACPA supporting a mechanism 








This project will address the following specific aims: 1) Determine in cross-section that 
ACPA is present in the lung of individuals in the preclinical period of RA, 2) Evaluate the 
longitudinal evolution of ACPA in the lung and serum of individuals in the preclinical period of RA 
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and 3) Identify immunologic mechanisms in the lung, such as inducible bronchus associated 




SPUTUM RHEUMATOID ARTHRITIS-RELATED ANTIBODIES IN CROSS-SECTION 
 
Background and Review of the Literature 
 
Rheumatoid arthritis (RA). RA is a chronic systemic autoimmune disease that affects 
approximately 1% of the population (1). RA is associated with significant morbidity, increased 
mortality and over $30 billion dollars annually in US health-care related costs (2-4). Despite the 
millions of individuals impacted and the unfavorable disease-related outcomes, the exact etiology of 
RA remains unknown, including the site where autoimmunity initially develops. In order to reduce 
the adverse public health burden of RA, an improved understanding of the initiating factors, including 
the initiating site of autoimmunity in RA, is needed in order to develop prevention strategies for this 
devastating disease. 
 
Autoantibodies in RA. Several autoantibody systems have been described in RA, including 
antibodies to citrullinated protein/peptide antigens (ACPA), rheumatoid factor (RF) and the more 
recently identified antibodies to carbamylated proteins (5). Each of these antibody systems is unique, 
and each may play unique roles in the pathogenesis of RA. Herein, the focus will be on the ACPA 
system for several reasons. ACPAs are the most specific autoantibody for RA (6), and data suggest 
that ACPA is directly pathogenic in RA including studies that identified ACPA associated with 
increased synovial lymphocyte infiltration and joint destruction in RA (7-9). ACPA can also directly 
target certain joint proteins (10), and ACPA can independently induce osteoclasts and synovitis in 
experimental models (11-14). These data suggest that an improved understanding of ACPA 
development can provide critical insight into the overall pathogenesis of RA. 
Citrullination is the post-translational modification of peptidyl-arginine to peptidyl-citrulline 
that is facilitated by the enzyme peptidylarginine deiminase (PAD) (15). Citrullination is a naturally 
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occurring physiological process that occurs under common biologic conditions such as gene 
regulation and inflammation (16, 17). One mechanism by which citrullination could lead to an 
immune response in some individuals is that citrullination can modify the structure of the protein, and 
this structural change could expose previously concealed arginine residues that upon citrullination 
would be neo-antigens exposed to the immune system (18). Citrullination can also alter the 
presentation of peptides to immune cells, including CD4+ T cells, resulting in a more immunogenic 
response (19). However, it is unclear why some, and not all, individuals generate antibodies to certain 
citrullinated proteins. 
In patients with RA, several individual ACPAs have been identified including citrullinated 
fibrinogen, citrullinated vimentin, citrullinated alpha-enolase and citrullinated fillagrin (20, 21). 
Commercial assays are not available to detect the presence of these individual ACPAs, but there is a 
commercial anti-cyclic citrullinated peptide (CCP) assay that detects antibody reactivity to multiple 
synthetic RA-related citrullinated peptides (22). Anti-CCP assays are routinely used clinically in the 
diagnosis of RA, anti-CCP antibodies are highly specific for RA in the setting of inflammatory 
arthritis (>93%) (6), and the presence of anti-CCP antibodies is associated with more severe joint 
damage (9) in RA making this assay relevant in the pathogenesis of RA.  
 
Preclinical period of RA. RA is clinically diagnosed after the onset of inflammatory arthritis 
(23, 24). However, there is a period of RA development during which systemic RA-related 
autoantibodies, including ACPA, are detectable in the blood on average 3-5 years prior to the onset of 
inflammatory arthritis (6, 25, 26). This period of systemic autoimmunity in the absence of 
inflammatory arthritis is often termed the ‘preclinical’ period of RA. Preclinical RA is clearly 
distinguished from clinically classified RA because during the preclinical period of systemic 
autoimmunity, there is no inflammation in the joints based on studies of clinical examination, 
magnetic resonance imaging and synovial biopsy (27, 28). In addition, the preclinical period 
highlights several critical points relevant to the development of RA. First, RA develops in multiple 
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phases as outlined in Figure 1 that can progress from genetic risk to the preclinical period of 
autoimmunity and ultimately to the onset of inflammatory arthritis that is classified as RA. Second, 
the absence of inflammatory arthritis in preclinical RA indicates that RA-related antibodies originate 
at a site outside of the joint, and this point will be discussed in more detail below. Third, multiple data 
demonstrate that serum ACPA elevations in the absence of inflammatory arthritis are highly 
predictive of the future development of classified RA (6, 29-34) thereby supporting that individuals 
with serum ACPA positivity are highly valuable to study in order to understand the initiating 
processes in the development of RA. Finally, in recent years, there have been significant treatment 
advances in RA including the finding that earlier initiation of treatment improves long-term outcomes 
(35-37). As such, it is hypothesized that treatment during the preclinical period may be able to 
prevent RA. However, further understanding of the preclinical period of RA is needed to 


















Figure 1. Phases of RA development. The figure depicts the different phases of RA development 
including the preclinical period of RA that precedes the development of classified RA.  
 
 
ACPA isotypes. Different antibody isotypes of the immune system can have unique 
pathogenic features. For example, immunoglobulin (Ig)-G is more effective than IgA at pathogen 
opsonization and activation of the complement system (38). IgA is also the predominant antibody 
 
          






















history of RA  
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isotype of the mucosal immune system and may be particularly relevant to mucosal generation of 
antibodies. Both ACPA-IgG and ACPA-IgA are highly prevalent in the serum of patients with 
classified RA (9, 39-43). Both are also specific for classified RA and associated with higher disease 
activity in RA, supporting their role in RA pathogenesis (9, 39-43). While ACPA-IgG and ACPA-
IgA are associated with RA, these two ACPA isotypes also demonstrate some important differences 
in RA. For example, the prevalence of serum ACPA-IgG is higher in patients with classified RA 
compared to RA-free individuals with a familial risk of RA who were more often serum ACPA-IgA 
positive (41, 42). This has generated a hypothesis that perhaps the development of ACPA-IgG is 
important in the transition to clinically apparent arthritis (44). In addition, the risk factors associated 
with serum ACPA-IgG and ACPA-IgA positivity in RA patients differ. Specifically, ACPA-IgG is 
more strongly associated with RA genetic risk alleles, whereas ACPA-IgA is more strongly 
associated with smoking (45). Overall, understanding the development of both ACPA-IgG and 
ACPA-IgA can provide important insight into the pathogenesis of RA. 
 
Genetic and environmental risk factors in RA. Established data support that the etiology of 
RA involves the interaction of genetic risk alleles and certain environmental factors. Studies reveal 
that as much as 60% of RA risk can be explained by genetics (46), and while genetics can play a 
smaller role in some individuals, this finding also supports that additional factors beyond genetics 
play a role in the development of RA. To date, approximately 100 different genetic risk alleles have 
been identified in association with RA (47), and of these different risk alleles, the ‘shared epitope’ 
remains the strongest genetic risk factor identified in RA (48). The shared epitope refers to a group of 
specific human leukocyte antigen (HLA)-DRB1 alleles that have been associated with RA and share a 
5-amino acid sequence motif in the hypervariable region of the β1 domain of the HLA-DR molecule 
(48). It is often hypothesized that the shared epitope influences RA risk through either thymic 
selection of autoreactive T cells or through antigen presentation of particular autoantigens. However, 
it is of particular interest that recent data suggest that the shared epitope may be more strongly 
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associated with developing inflammatory arthritis in RA rather than playing a major role in the initial 
development of autoimmunity in RA (49, 50). 
Regarding environmental risk factors in RA, there is a wide range of different environmental 
factors that have been associated with an increased risk of RA [reviewed in (51)]. Relevant to this 
project, many of the risk factors for RA are inhaled and could directly impact the lung (52). In 
particular, cigarette smoking is the strongest known risk factor for RA. In fact, in an individual who 
has two copies of the shared epitope allele, smoking was associated with a 21-fold increased risk of 
RA (52). However, not all individuals who develop RA have smoked, and other inhaled risk factors 
that have been associated with RA risk include silica dust and air pollution (53, 54). It is of note that 
the majority of these studies have evaluated individuals who have already developed classified RA, 
and it may be that the risk factors influencing ACPA development differ from those that influence the 
transition to inflammatory arthritis.  
 
Lung associations in RA. In addition to the association of inhaled factors and RA, there are 
several other lung related features associated with RA. There is a high prevalence (50-70%) of lung 
disease in classified RA patients, including both parenchymal and airways disease (55-57). Lung 
disease is even highly prevalent in early, untreated RA (58). In addition, recent data using mass 
spectrometry identified a shared citrullinated vimentin antigen that was present in the lung and joint 
tissue of classified RA patients, suggesting a potential shared target for ACPA that could link the lung 
and joints in RA (59).  
Regarding ACPA and the lung in RA, ACPA positive RA patients have a higher prevalence 
of airways and parenchymal lung disease as well as lymphocytic infiltration of lung tissue compared 
to ACPA negative RA patients and controls (58). Lung tissue in ACPA positive RA patients also 
demonstrates higher levels of plasma cells, T cells, B cells, markers for immune activation such as 
HLA-DR and HLA-DQ and markers of T cell activation such as CD69 (58). Although it will be 
discussed in more detail in Chapter V, lung tissue from RA patients demonstrates inducible bronchus 
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associated lymphoid tissue (iBALT) containing plasma cells generating ACPA (60). It is also of 
interest that smoking, which is a known risk factor for RA, can increase the amount of citrullinated 
protein and PAD2 expression in the lung (61, 62), and while these studies did not investigate whether 
increased citrullinated protein levels were associated with ACPA generation in the lung, it supports 
that the antigenic targets of ACPA increase locally in the lung with smoking which could raise the 
potential to trigger local ACPA production. 
Regarding the lung and the preclinical period of RA, lung disease has been described to 
precede joint disease in a number of patients who later developed classified RA (27, 63, 64). Data 
from our group has identified a significantly higher prevalence of inflammatory airway abnormalities 
consistent with inflammation on imaging in RA-free subjects with systemic RA-related autoimmunity 
compared to subjects without RA-related autoantibodies (27). This finding was present for ACPA and 
present even in never smokers. In addition, our group identified the presence of RA-related antibodies 
in the sputum of subjects with early classified RA and subjects At-Risk for RA (65). However, this 
study was performed in a small number of individuals and did not address isotype specific ACPAs in 
the lung. 
   
Overall hypothesis. Based on the aggregate data describe above, our proposed model of 
ACPA and RA development is outlined in Figure 2. In this figure, an environmental factor (e.g. 
smoking) interacts with the immune system at the airway mucosa. In some individuals, this 
interaction results in an inflammatory reaction that triggers an autoimmune response in the form of 
ACPA generation that is initially localized to the lung. Over time, however, this autoimmunity may 
become systemic, and after several years, clinically evident inflammatory arthritis develops that can 
be classified as RA. In the studies described herein, we will be primarily investigating Steps 3 and 4 
of this proposed model. 
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Figure 2. Study hypothesis. The figure depicts a stepwise description of the overall study hypothesis 




Methodologies to sample the lung. Two commonly used methodologies for sampling 
biologic activity in the lung are bronchoscopy with broncho-alveolar lavage (BAL) and induced 
sputum sampling. Both of these methodologies have been used to study inflammation and the 
presence of RA-related autoantibodies in the lung (60, 66-72).  However, BAL is invasive, expensive 
and associated with procedural risk making it a difficult modality to utilize for large-scale studies of 
preclinical RA or longitudinal studies that require repeated sampling. Alternatively, induced sputum 
collection is a non-invasive methodology that is cheaper, safer and easier to repeat over time. In 
addition, BAL and sputum sample different regions of the lung. BAL samples the lower respiratory 
tract that contains predominately IgG antibodies and is made up of >90% macrophages, while sputum 
samples the upper respiratory tract that contains predominately IgA antibodies and is made up of both 
macrophages and neutrophils (58, 73-75).  Because sputum primarily samples the milieu of the 
airway mucosa, such sampling could be considered optimal in order to study the lung in preclinical 






1 The figure is published with permission at Demoruelle MK, Deane KD, Holers VM. When and where does inflammation 
begin in rheumatoid arthritis? Curr Opin Rheumatol. 2014 Jan;26(1):64-71. PMC4033623 
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Methods and Analysis Plan 
 
Study design. This is a cross-sectional observational cohort study. 
 
Subjects. Subjects were recruited from the Studies of the Etiology of RA (SERA) cohort that 
is a well-established observational cohort designed to investigate the natural history of RA through 
the prospective study of individuals who have an increased risk of developing RA in the future (76). 
This study included subjects from the SERA cohort who are At-Risk for developing RA in the future 
as well as subjects with classified RA and healthy Controls.  
 
At-Risk subjects. We included 180 subjects who were determined to be At-Risk for 
the future development of RA based on familial or serologic risk factors. Familial risk was 
defined as having a first-degree relative with classified RA which has been associated with a 
3-9 fold increased risk of developing RA in the future (77, 78). Serologic risk was defined as 
having serum anti-CCP positivity using a commercial assay (CCP3.1) identified through 
clinical, community or research based screening, and serum anti-CCP positivity is strongly 
associated with future development of RA (6, 79). Of the 180 At-Risk subjects, 115 (64%) 
had only a familial risk factor, 42 (23%) had only a serologic risk factor, and 23 (13%) had 
both a familial and serologic risk factor. All At-Risk subjects were without clinical evidence 
of inflammatory arthritis.  
 
RA subjects. We included 70 subjects with classified RA. RA diagnosis was 
confirmed by a medical chart review performed by a board certified rheumatologist, and all 
RA subjects met the 2010 American College of Rheumatology/European League Against 
Rheumatism RA classification criteria (23). All RA subjects in this study were also serum 
anti-CCP positive based on commercial CCP3.1 assay.  
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Healthy Control subjects. We included 140 Healthy Control subjects who were 
without RA, without inflammatory arthritis and did not have a first-degree relative with RA. 
All Controls were serum anti-CCP negative based on commercial CCP3.1 assay. From the 
total 140 Controls, 80 were randomly selected to serve as Cut-Off Controls and the remaining 
60 served as Comparator Controls. Cut-Off Controls were used to establish cut-off levels for 
sputum antibody positivity, and Comparator Controls were used for comparative analyses 
with At-Risk and RA subjects.  
 
Study visit. Each subject had a baseline study visit during which they completed 
questionnaires to obtain the following information: demographics, medical history, current 
medication use, smoking history, self-reported history of pneumonia, acute bronchitis or chronic lung 
disease. The presence of chronic lung disease was determined by self-report using a questionnaire that 
asked if subjects had a health care provider diagnosed history of asthma, emphysema, chronic 
bronchitis, bronchiectasis, interstitial lung disease, lung cancer, pulmonary artery hypertension, 
obstructive sleep apnea or other chronic lung disease. Subjects without RA also underwent a 68-count 
joint examination performed by a study rheumatologist to ensure no clinical evidence of 
inflammatory arthritis at baseline. In addition, subjects underwent a blood draw and an induced 
sputum collection, as described below. 
 
Genetic testing. Testing for the shared epitope was performed on blood samples at the 
Benaroya Research Institute at Virginia Mason in Seattle, WA through an ongoing research 
collaboration. A targeted approach was used that is a modification of real-time polymerase chain 
reaction (PCR) and includes sequence-specific primers and probes for HLA-DR4 subtyping (80). The 
alleles considered to contain the shared epitope were as follows: DRB1*04:01, 04:04, 04:05, 04:08, 
04:09, 04:10, and DR1 01:01 and 01:02.   
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Induced sputum collection. Induced sputum was collected and processed using established 
protocols (65, 81, 82). First, subjects underwent an oral wash with water prior to sputum induction to 
minimize salivary contamination. Next, subjects inhaled hypertonic nebulized saline over 15 minutes. 
Throughout the 15 minutes, subjects were instructed to collect any samples from spontaneous 
coughing in a sputum collection cup.  To further minimize salivary contamination, subjects were 
given a separate plastic container and instructed to spit any saliva into the separate container. They 
were instructed to only use the sputum collection cup when producing a sample from coughing. After 
15 minutes, subjects were requested to perform several deep coughs and collect any sample produced 
from coughing in the sputum collection cup. 
After sputum collection, the entire sputum sample underwent a weight-based dilution with 
phosphate buffer solution (PBS). Dilution was followed by mechanical homogenization using a 
syringe and 18-gauge needle. A mucolytic agent such as dithiothreitol was not added to the sample 
during processing because of its mechanism of action that includes the destruction of disulfide bonds, 
which would disrupt the structure and confirmation of any antibody in the sample. After dilution and 
homogenization, samples were centrifuged at 1500g, and proteinase inhibitors phenylmethylsulfonyl 
fluoride and ethylenediaminetetraacetic acid were added to the supernatant to preserve the integrity of 
proteins in the sample. 
All sputum had microscopic evaluation to determine the amount of squamous epithelial cells 
in each sample, which is a marker of salivary content. In addition, samples collected after September 
2013 underwent a manual cell count and cell differential that was performed using a hemocytometer 
and cytocentrifugation, respectively. All samples used in the study were consistent with a lower 
airway origin defined as having < 10 squamous epithelial cells per high power field on light 
microscopy or < 80% squamous epithelial cells on cell differential (81, 83).  
For all sputum biomarker testing, the cell-free supernatant was used. Because sputum 
samples were diluted with PBS during processing, all sputum results were multiplied by the sample’s 
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dilution factor in order to appropriately compare results between subjects while accounting for 
different dilutions used during sample processing. 
 
ACPA testing. All serum and processed sputum underwent ACPA testing using the 
commercial CCP3.1 ELISA assay (IgG/IgA, Inova Diagnostics Inc., San Diego, CA, USA). Serum 
was tested as per manufacturer instructions, and the cut-off level for positivity was that recommended 
by the manufacturer (≥ 20 ELISA units). For sputum testing, similar protocols were used except that 
processed sputum was substituted for serum in each assay well. All testing was performed in the 
University of Colorado Division of Rheumatology Clinical Research Laboratory. 
Because CCP3.1 detects both IgG and IgA reactivity without the ability to discriminate the 
exact isotypes present, in a random subset of samples, we also tested for individual anti-CCP isotypes 
(CCP-IgG and CCP-IgA) using a CCP3 plate and the respective conjugate (Inova Diagnostics Inc, 
San Diego, CA, USA; for research only). For anti-CCP isotypes, a positive control sample was 
provided by the manufacturer for each isotype, and results for anti-CCP isotype levels in sputum and 
serum are reported in relative units based on the optical density (OD) of the subjects’ sample divided 
by the OD of the positive control. This approach allowed us to account for any plate-to-plate 
variation. For sputum anti-CCP3.1 and all anti-CCP isotype testing, cut-off levels for positivity were 
set at a level that was present in < 5% of our healthy Cut-Off Control subjects therefore 
corresponding to a level above the 95
th
 percentile in Cut-Off Controls.  
To determine the CCP assay’s background absorption, we tested 5 blank wells with no 
sample using a CCP3 ELISA plate. Because the CCP3 plate is the plate used for the CCP3.1, CCP-
IgA and CCP-IgG assays, these results were applied to all 3 tests. We found that the average OD of 
the blank wells plus 2 standard deviations (SD) was an OD of 0.08. Therefore, any sputum or serum 
result for CCP3.1, CCP-IgA or CCP-IgG that had an average OD ≤ 0.08 was considered to have an 
undetectable level of zero.  We further verified the background level of ≤ 0.08 using serial dilutions 
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of a positive serum sample, and this verification confirmed that at ≤ 0.08, the inherent assay 
background obscured any further drop in signal. 
In this study, serum and sputum anti-CCP levels were measured in duplicate wells. For 
sputum, the mean coefficient of variation between wells was 5.2% for anti-CCP3.1, 4.8% for anti-
CCP-IgA and 5.3% for anti-CCP-IgG. To further validate the anti-CCP isotype assays, which are not 
commercial assays, we tested serum from 6 non-RA subjects, 3 with a high anti-CCP isotype levels 
and 3 with low levels. We tested serum from these 6 subjects in 10 wells each in order to determine 
intra-assay variability. The mean coefficient of variation was 8.4% for anti-CCP-IgA and 8.0% for 
anti-CCP-IgG.   
 
Total Ig testing. In a random subset of subjects who had adequate sputum volume available, 
total IgG and total IgA level (mg/dL) were tested for sputum (Siemens BN II nephelometry 
cerebrospinal fluid assessment system) and serum (Beckman-Coulter Synchron nephelometry 
system). 
 
Analytic approach. Prevalence of sputum anti-CCP positivity was compared between groups 
using Chi-square or Fisher’s exact test, as appropriate. Prevalence of sputum anti-CCP isotype 
positivity within each group was compared using McNemar’s test. Because sputum anti-CCP levels 
followed a non-normal distribution, non-parametric testing was used to compare median anti-CCP 
levels across groups (Mann-Whitney U). To perform correlation analyses with sputum cell counts, 
because of the non-normal distribution, anti-CCP and sputum cell count levels were log transformed, 
and correlation was determined using Pearson’s correlation coefficient. Agreement between CCP 
assays was determined using Cohen’s kappa coefficient. Logistic regression was also used to evaluate 
the relationship between sputum anti-CCP positivity and group while adjusting for ever-smoking. 
Wilcoxon matched pairs signed rank test was used to compare the ratios of anti-CCP/Ig between 
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sputum and serum within each group. Analyses were performed using SPSS (version 23) and SAS 




Subject characteristics. Subject characteristics are listed in Table 1. At-Risk and RA 
subjects were older and more often shared epitope positive compared to Controls. RA subjects were 
less likely to be non-Hispanic white and more likely to be current smokers compared to At-Risk and 
Control subjects. There was no difference in sex, history of chronic lung disease or history of 
pneumonia or bronchitis between the groups.  
 
 
Sputum anti-CCP positivity in all subjects. Nineteen of 180 (10.6%) At-Risk subjects were 
positive for anti-CCP3.1 that detects both IgG and IgA reactivity (Table 2). When considering 












Age, mean (SD) 38 (15)  42 (15) 53 (15) 52 (12) <0.01 
Female, N (%) 57 (71) 48 (80) 120 (67) 50 (71) 0.27 
Non-Hispanic white, N (%)2 59 (75) 47 (81) 136 (76) 42 (63) 0.09 
Ever-smoker, N (%) 21 (26) 13 (22) 59 (33) 32 (46) 0.02 
Current-smoker, N (%) 2 (3) 1 (2) 9 (5) 11 (16) <0.01 
Shared epitope (≥1 allele), N (%)3 17 (34) 18 (39) 83 (53) 40 (68) <0.01 
History of chronic lung disease, N (%) 13 (16) 9 (15) 39 (22) 20 (29) 0.18 
History of pneumonia, N (%) 23 (29) 12 (20) 50 (28) 18 (26) 0.64 
History of acute bronchitis, N (%) 23 (29) 21 (35) 64 (36) 20 (29) 0.59 
1. P-value is calculated comparing groups using ANOVA for age and Chi-square or Fisher’s exact test for 
other characteristics.  
2. One Cut-Off Control, 2 Comparator Controls, 2 At-Risk and 3 RA subjects declined to answer the 
question of their race. 
3.  Fifty of 80 Cut-Off Controls, 46/60 Comparator Controls, 158/180 At-Risk and 59/70 RA subjects had 
blood testing for the presence of the shared epitope. 
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individual antibody isotypes, 14/112 (12.5%) of At-Risk subjects were sputum positive for anti-CCP-
IgG and 21/112 (18.8%) were sputum positive for anti-CCP-IgA. Within the At-Risk subjects with 
individual isotype testing, sputum anti-CCP-IgA was non-significantly more prevalent than anti-CCP-
IgG (18.8% vs. 12.5%, p=0.28). The prevalence of positivity for sputum anti-CCP3.1 and anti-CCP-
IgG was similar between At-Risk and Comparator Control subjects (p=0.81 and p=1.0, respectively), 
whereas sputum anti-CCP-IgA positivity was higher in At-Risk subjects compared to Controls 
(18.8% vs. 3.3%, p<0.05). 
 
In addition, 46 of 180 (25.6%) At-Risk subjects were positive for any anti-CCP antibody in 
sputum (i.e. CCP3.1, CCP-IgG or CCP-IgA), and in the 112 At-Risk subjects tested for individual 
CCP isotypes, 33/112 (29.5%) were positive for either sputum anti-CCP-IgG or anti-CCP-IgA. The 
agreement between anti-CCP3.1 and anti-CCP-IgG or anti-CCP-IgA in sputum was poor 
(kappa=0.20), and this poor agreement was primarily driven by the 27/104 (26.0%) of anti-CCP3.1 
negative At-Risk subjects who were positive for either anti-CCP-IgG or anti-CCP-IgA in sputum. The 
majority of At-Risk subjects with sputum anti-CCP3.1 positivity were also sputum anti-CCP-IgG or 
anti-CCP-IgA positive [6/8 (75.0%)]. 























CCP3.1 (IgG/IgA) (+) 5/60 (8) 19/180 (11)  25/70 (36) 0.81 <0.01 <0.01 
CCP-IgG (+) 4/30 (13) 14/112 (13) 26/44 (59) 1.0 <0.01 <0.01 
CCP-IgA (+) 1/30 (3) 21/112 (19) 14/44 (32) <0.05 0.01 0.08 
CCP3.1, CCP-IgG or 
CCP-IgA (+) 
10/60 (17) 46/180 (26) 40/70 (57) 0.16 <0.01 <0.01 
CCP-IgG or CCP-IgA (+) 5/30 (8) 33/112 (30) 28/44 (64) 0.25 <0.01 <0.01 
1. All results are reported as number of subjects who were positive/total number of subjects, (%) 
2. P-value is calculated comparing prevalence of positivity between groups using Chi-square or Fisher’s 
exact test.  
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In RA, 25/70 (35.7%) subjects were sputum anti-CCP3.1 positive, 26/44 (59.1%) were 
sputum anti-CCP-IgG positive and 14/44 (31.8%) were sputum anti-CCP-IgA positive (Table 2). 
Forty of 70 (57.1%) were positive for any anti-CCP antibody in sputum (i.e. CCP3.1, CCP-IgG or 
CCP-IgA), and in the 44 RA subjects tested for individual CCP isotypes, 28/44 (63.6%) were positive 
for either sputum anti-CCP-IgG or anti-CCP-IgA. Similar to At-Risk subjects, the agreement between 
sputum anti-CCP3.1 and anti-CCP-IgG or anti-CCP-IgA in RA subjects was poor (k=0.39), and the 
poor agreement was primarily driven by the 15/31 (48.4%) sputum anti-CCP3.1 negative RA subjects 
who were positive for sputum anti-CCP-IgG or anti-CCP-IgA. Also similar to At-Risk subjects, the 
majority of RA subjects with sputum anti-CCP3.1 positivity were also sputum anti-CCP-IgG or anti-
CCP-IgA positive [13/13 (100%)]. 
The prevalence of positivity for sputum anti-CCP3.1 and anti-CCP-IgG was significantly 
higher in RA subjects compared to At-Risk and Control subjects (all p≤0.05), whereas sputum anti-
CCP-IgA positivity was non-significantly higher in RA compared to At-Risk subjects (31.8% vs. 
18.8%, p=0.08). When comparing the prevalence of positivity for sputum anti-CCP isotypes within 
RA subjects, sputum anti-CCP-IgG was more positive compared to anti-CCP-IgA positivity (59.1% 
vs. 31.8%, p<0.01). 
In addition to prevalence of positivity, sputum anti-CCP3.1, anti-CCP-IgA and anti-CCP-IgG 
levels were significantly higher in RA subjects compared to Controls (Figure 3). In addition, sputum 
anti-CCP3.1 and anti-CCP-IgG levels were higher in RA compared to At-Risk subjects (p<0.01), 
whereas sputum anti-CCP-IgA levels were similar between RA and At-Risk subjects (p=0.28). 
 
Sputum anti-CCP positivity stratified by serum anti-CCP status in At-Risk subjects. We 
stratified At-Risk subjects based on serum anti-CCP3.1 positivity, with the assumption that serum 
anti-CCP negative At-Risk subjects are likely in an earlier phase of ACPA/RA development 
compared to serum anti-CCP positive At-Risk subjects. This stratification resulted in 115 serum anti-
CCP3.1 negative and 65 serum anti-CCP3.1 positive At-Risk subjects. There was no significant 
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difference in age, sex, race, history of smoking, lung disease, pneumonia or bronchitis between the 
two groups (Table 3); however, serum anti-CCP positive At-Risk subjects were less likely than serum 
anti-CCP negative At-Risk subjects to be shared epitope positive (39.6% vs. 58.6%, p=0.03). 
 
Figure 3. Sputum anti-CCP levels. The figure depicts sputum anti-CCP3.1 (Panel A), anti-CCP-IgG 
(Panel B) and anti-CCP-IgA (Panel C) levels in Cut-Off Controls, Comparator Controls, At-Risk and 





Table 3. Subject characteristics of At-Risk subjects stratified by serum anti-CCP3.1 status 
 
 
Serum CCP3.1 (-) 
At-Risk 
(N=115) 






Age, mean (SD) 52 (15) 55 (15) 0.12 
Female, N (%) 79 (69) 41 (63) 0.44 
Non-Hispanic white, N (%)
2
 85 (75) 51 (80) 0.44 
Ever-smoker, N (%) 38 (33) 21 (32) 0.92 
Current-smoker, N (%) 4 (4) 5 (8) 0.29 
Shared epitope (≥1 allele), N (%)
3
 64 (58) 19 (40) 0.03 
History of chronic lung disease, N (%) 20 (17) 19 (29) 0.06 
History of pneumonia, N (%) 29 (25) 21 (32) 0.31 
History of acute bronchitis, N (%) 39 (34) 25 (39) 0.54 
1. P-value is calculated comparing groups using t-test for age and Chi-square or Fisher’s exact test 
for other characteristics.  
2. One serum anti-CCP3.1(-) and 1 serum anti-CCP3.1(+) At-Risk subject declined to answer the 
question of their race. 
3. One-hundred ten of 115 serum anti-CCP3.1(-) and 48/65 serum anti-CCP3.1(+) At-Risk 
subjects had blood testing for the presence of the shared epitope alleles. 



































































































































When At-Risk subjects were stratified by serum anti-CCP3.1 status, serum anti-CCP3.1 
positive At-Risk subjects had a higher prevalence of sputum anti-CCP3.1 positivity compared to 
Comparator Controls (23.1% vs. 8.3%, p=0.03) as well as for sputum anti-CCP-IgA (31.3% vs. 3.3%, 
p<0.01) (Table 4). In contrast, serum anti-CCP3.1 negative At-Risk subjects had a prevalence of 
positivity similar to that in Comparator Controls for each of the sputum anti-CCP antibodies (Table 
4). When comparing serum anti-CCP3.1 positive and negative At-Risk subjects, serum anti-CCP3.1 
positive At-Risk subjects had a higher prevalence of sputum anti-CCP3.1 and anti-CCP-IgG (both 
p<0.01). In addition, within serum anti-CCP3.1 positive At-Risk subjects, the prevalence of sputum 
anti-CCP-IgG and anti-CCP-IgA was similar (28.1% vs. 31.3%, p=1.0), but within serum anti-
CCP3.1 negative At-Risk subjects, there was a non-significantly higher prevalence of sputum anti-
CCP-IgA compared to anti-CCP-IgG positivity (13.8% vs. 6.3%, p=0.21).  
 
To further consider the relationship between sputum and serum anti-CCP isotypes, we 
evaluated sputum anti-CCP isotype positivity stratified by serum anti-CCP isotype positivity or 
negativity. Of the 25 serum anti-CCP-IgA positive At-Risk subjects, 9 (36.0%) were also sputum 
anti-CCP-IgA positive and 16 (64%) were sputum anti-CCP-IgA negative (Table 5). In addition, of 
the 87 serum anti-CCP-IgA negative At-Risk subjects, 12 (13.8%) were sputum anti-CCP-IgA 
positive supporting that in these subjects, anti-CCP-IgA antibodies are originating in the lung and are 
not simply translocated from the blood. Similar results were demonstrated for anti-CCP-IgG in At-
























Serum CCP (-) v. 
Serum CCP (+) 
At-Risk 
p-value2 
CCP3.1 (IgG/IgA) (+) 5/60 (8) 4/115 (4) 15/65 (23) 0.28 0.03 <0.01 
CCP-IgG (+) 4/30 (13) 5/80 (6) 9/32 (28) 1.0 0.08 <0.01 
CCP-IgA (+) 
1/30 (3) 11/80 (14) 10/32 (31) 0.51 <0.01 0.02 
1. All results are reported as number of subjects who were positive/total number of subjects, (%) 
2. P-value is calculated comparing prevalence of positivity between groups using Chi-square or Fisher’s exact test.  
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Risk subjects in which there were 40 serum anti-CCP-IgG positive At-Risk subjects of whom 10 
(25.0%) were also sputum anti-CCP-IgG positive, and there were 72 serum anti-CCP-IgG negative 
At-Risk subjects of whom 4 (5.6%) were sputum anti-CCP-IgG positive. 
 
In RA subjects, 24 were serum anti-CCP-IgA positive of whom 14 (58.3%) were also sputum 
anti-CCP-IgA positive and 10 (41.7%) were sputum anti-CCP-IgA negative (Table 4). All 20 RA 
subjects who were serum anti-CCP-IgA negative, were also sputum anti-CCP-IgA negative. 
Furthermore, there were 43 serum anti-CCP-IgG positive RA subjects of whom 26 (60.5%) were 
sputum anti-CCP-IgG positive and 17 (39.5%) were sputum anti-CCP-IgG negative. There was only 
one serum anti-CCP-IgG negative RA subject, and this RA subject was also sputum anti-CCP-IgG 
negative. 
 
 Ratios of anti-CCP to total Ig level in sputum and serum. One method that can be used to 
compare antibodies between two different anatomic sites is to compare the ratio of antibody level to 
total Ig level between two sites with the rationale that if the antibody is being generated or 
sequestered at a particular site, it will have a higher antibody/Ig ratio at that site compared to the ratio 
in the blood (84-86). For our studies, we compared the ratios of anti-CCP level to total Ig level for 
each isotype in sputum and serum in order to evaluate whether anti-CCP was being generated in the 
lung as well as to determine the potential for translocation of anti-CCP antibodies from serum to 
sputum.  
Table 5. Sputum anti-CCP isotype positivity stratified by serum anti-CCP isotype status
1
 










Serum CCP-IgA (+) 9/25 (36) 16/25 (64) 14/24 (58) 10/24 (42) 









Serum CCP-IgG (+) 10/40 (25) 30/40 (75) 26/43 (61) 17/43 (40) 
Serum CCP-IgG (-) 4/72 (6) 68/72 (94) 0/1 (0) 1/1 (100) 
1.   All results are reported as number of subjects (%) 
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 In the subset of At-Risk subjects tested, the majority demonstrated a higher anti-CCP/Ig ratio 
in the sputum compared to serum for anti-CCP3.1 and anti-CCP-IgA. Specifically, for the anti-
CCP3.1/total IgG+IgA ratio, 79/95 (83.2%) of At-Risk subjects had a higher ratio in sputum, and for 
anti-CCP-IgA, 53/95 (55.8%) had a higher ratio in sputum. When considering only subjects with 
positive sputum antibodies, 4/7 (57.1%) sputum anti-CCP3.1 positive At-Risk subjects and 11/19 
(57.9%) sputum anti-CCP-IgA positive At-Risk subjects had a higher respective anti-CCP/Ig ratios in 
the sputum compared to the serum. When considering all At-Risk subjects and anti-CCP-IgG, only 
10/95 (10.5%) had an anti-CCP-IgG/total IgG ratio higher in sputum compared to serum; however, 
44/95 (46.3%) had undetectable levels in both sputum and serum. Therefore, when considering only 
sputum anti-CCP-IgG positive At-Risk subjects, 7/10 (70%) had a higher anti-CCP/Ig ratio in the 
sputum.  
In all RA subjects, the number of subjects demonstrating a higher anti-CCP/Ig ratio in sputum 
for anti-CCP3.1 and anti-CCP-IgA was lower than in At-Risk subjects. Specifically, for the anti-
CCP3.1/total IgG+IgA ratio, 6/30 (20.0%) RA subjects had a higher anti-CCP/Ig ratio in the sputum 
compared to 83.2% of At-Risk subjects (p<0.01). For anti-CCP-IgA/total IgA, 10/30 (33.3%) RA 
subjects had a higher ratio in the sputum compared to 55.8% of At-Risk subjects (p=0.03). In 
contrast, more RA subjects than At-Risk subjects had a higher anti-CCP-IgG/total IgG in sputum 
compared to serum. Specifically, 14/30 (46.7%) RA subjects had a higher anti-CCP-IgG/total IgG in 
sputum compared to 10.5% of At-Risk subjects (p<0.01). Furthermore, 14/17 (82.4%) sputum anti-
CCP-IgG positive RA subjects had a higher anti-CCP-IgG/total IgG ratio in the sputum compared to 
serum, which was similar to the rates demonstrated in At-Risk subject (82.4% vs. 70.0%, p=0.64). Of 
note, the differences between At-Risk and RA subjects may be reflective of the higher prevalence of 
serum anti-CCP positivity in RA subjects. In addition, the synovium in classified RA patients but not 
in At-Risk subjects has been shown to consist of germinal centers producing ACPA locally, and it 
may be that in classified RA, the accumulation of multiple sites generating ACPA could explain the 
lower number of RA subjects in our study that have anti-CCP/Ig ratios higher in sputum (28, 86).  
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Overall, these data indicate that many, but not all, At-Risk and RA subjects demonstrate generation of 
anti-CCP antibodies in the sputum.  
In addition, for anti-CCP-IgG, the median level of anti-CCP-IgG/total IgG was higher in 
sputum than in serum for sputum anti-CCP-IgG positive At-Risk and RA subjects (Figure 4, Panels B 
and D). Whereas, for anti-CCP-IgA, the median anti-CCP-IgA/total IgA level was not higher in 
sputum compared to serum for sputum anti-CCP-IgA positive At-Risk or RA subjects (Figure 5, 
Panels B and D). 
 
Figure 4. Ratios of anti-CCP-IgG/total IgG in sputum and serum. The figure depicts the ratio of 
anti-CCP-IgG level to total IgG level in the sputum and serum for all At-Risk subjects (Panel A), 
sputum anti-CCP-IgG(+) At-Risk subjects (Panel B), all RA subjects (Panel C) and sputum anti-CCP-
IgG(+) RA subjects (Panel D). P-values compare median levels between sputum and serum 





























































































































B. Sputum CCP-IgG (+) At-Risk





Figure 5. Ratios of anti-CCP-IgA/total IgA in sputum and serum. The figure depicts the ratio of 
anti-CCP-IgA level to total IgA level in the sputum and serum for all At-Risk subjects (Panel A), 
sputum anti-CCP-IgA(+) At-Risk subjects (Panel B), all RA subjects (Panel C) and sputum anti-CCP-
IgA(+) RA subjects (Panel D). P-values compare median levels between sputum and serum 
(Wilcoxon matched pairs signed rank test).  
 
 
Sputum anti-CCP antibodies stratified by subject characteristics. Because smoking is 
associated with risk for developing serum anti-CCP-positive RA and can influence sputum studies 
(52), we analyzed subjects stratified based on their self-reported history of ever smoking >100 
cigarettes in their lifetime. In At-Risk subjects, sputum anti-CCP-IgA positivity was significantly 
more prevalent in ever-smokers compared to never-smokers [12/39 (30.8%) vs. 9/73 (12.3%), 
p=0.02], whereas similar rates of sputum anti-CCP-IgG positivity were present in ever compared to 
never-smokers [6/39 (15.4%) vs. 8/73 (11.0%), p=0.50]. In RA subjects, a similar but non-significant 
association was seen between ever and never-smokers for anti-CCP-IgA [9/21 (42.9%) vs. 5/23 
(21.7%), p=0.20]. For anti-CCP-IgG in RA subjects, ever-smokers also demonstrated non-

























































































































B. Sputum CCP-IgA (+) At-Risk




vs. 11/23 (47.8%), p=0.20], although this finding could be confounded by the association of smoking 
and classified RA. 
In additional stratified analyses, in At-Risk subjects, there were no associations of sputum 
anti-CCP3.1, anti-CCP-IgA or anti-CCP-IgG positivity and sex, race, presence of the shared epitope 
allele, or history of lung disease, pneumonia or bronchitis (p≥0.05). In addition, correlation analyses 
did not identify a significant correlation between age and sputum anti-CCP levels. In RA and Control 
subjects, there were also no significant correlations or associations between sputum anti-CCP 
antibodies and age, sex, race, shared epitope positivity, or history of lung disease, pneumonia or 
bronchitis (p≥0.05). 
 Because of the association between sputum anti-CCP-IgA and ever-smoking, we performed 
logistic regression analyses to account for the influence of ever-smoking. In these analyses, sputum 
anti-CCP-IgA remained significantly associated with RA group status when adjusting for ever-
smoking [OR=2.1 (95% CI 1.1-4.1)]. In addition, sputum anti-CCP-IgA positivity remained 
significantly associated with serum anti-CCP3.1 positive At-Risk subjects compared to Comparator 
Controls when adjusting for ever-smoking [OR=6.0 (95% CI 1.1-31.2)]. 
 
Sputum cell counts in association with sputum anti-CCP antibodies. Neutrophils and 
macrophages are the predominant cell types in sputum (81, 83). When comparing median sputum cell 
count levels between At-Risk, RA and Comparator Controls, there was no significant difference in 
the total number of non-squamous cells, neutrophils or macrophages (Table 6).  














Total non-squamous cells  38 (14-79) 43 (21-103) 59 (20-129) 0.33 
Total neutrophils 19 (5-41) 23 (8-63) 38 (11-80) 0.12 
Total macrophages 12 (5-29) 17 (5-40) 15 (6-33) 0.81 
1. All results are reported in median (IQR) in cells x10
4
/mL 
2. P-value compares median level between all groups using the Kruskal Wallis test 
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Using correlation analyses, there was a significant correlation between sputum cell counts 
and sputum anti-CCP positivity in At-Risk and RA subjects. In At-Risk subjects, the strongest 
correlations were between sputum total non-squamous cells, neutrophils and macrophages and anti-
CCP-IgA (all p<0.001) as well as anti-CCP3.1 levels (all p<0.001) (Figure 6). Similar but less 
significant correlations were demonstrated between RA subjects and anti-CCP3.1 [anti-CCP3.1 
correlations with total cells (r=0.33, p<0.05), neutrophils (r=0.32, p=0.06), and macrophages (r=0.41, 
p=0.01)]. There was no significant correlation between sputum cell counts and sputum anti-CCP-IgG 
level in At-Risk subjects or sputum anti-CCP-IgG or anti-CCP-IgA levels in RA subjects.  
 
 
Figure 6. Sputum cell count and anti-CCP level correlations in At-Risk subjects. The figure 
depicts the log-transformed level of sputum anti-CCP3.1 (Panels A-C) and sputum anti-CCP-IgA 
(Panels D-F) correlated with the log transformed level of sputum total non-squamous cells (Panels A 
and D), neutrophils (Panels B and E) and macrophages (Panels C and F). R and p-values are 
calculated using Pearson’s correlation coefficient.  
 
Furthermore, At-Risk subjects who had sputum anti-CCP positivity for any of the CCP assays 
tested (i.e. CCP3.1, CCP-IgG and/or CCP-IgA) had higher levels of sputum cell counts compared to 











































































































































































Sputum CCP3.1 in At-Risk subjects




sputum anti-CCP negative At-Risk subjects or sputum anti-CCP negative Controls (Table 7). 
Specifically, comparing sputum anti-CCP positive vs. sputum anti-CCP negative At-Risk subjects, 
sputum anti-CCP positive At-Risk subjects had higher sputum total cells (68.9 vs. 38.0 cells x10
4
/mL, 
p=0.02) and sputum macrophages (25.3 vs. 13.3 cells x10
4
/mL, p<0.01) and to a lesser degree higher 
levels of sputum neutrophils (30.0 vs. 17.5 cells x10
4
/mL, p=0.07). Comparing sputum anti-CCP 
positive At-Risk subjects vs. sputum anti-CCP negative Comparator Controls, sputum anti-CCP 
positive At-Risk subjects had higher sputum total cells (68.9 vs. 32.0 cells x10
4
/mL, p=0.02), sputum 
macrophages (25.3 vs. 11.3 cells x10
4
/mL, p=0.01) and sputum neutrophils (30.0 vs. 14.3 cells 
x10
4
/mL, p=0.04). Even in healthy Comparator Controls, there was a non-significantly higher level of 
sputum total cell count and neutrophils in those who had any sputum anti-CCP positivity (for total 
cells, 82.6 vs. 32.0 cells x10
4




In addition, sputum anti-CCP negative At-Risk and Comparator Controls had similar levels of 
sputum cell counts (for total cells, 38.0 vs. 32.0 cells x10
4
/mL, p=0.51; for macrophages, 13.3 vs. 
11.3 cells x10
4
/mL, p=0.62; for neutrophils, 17.5 vs. 14.3 cells x10
4
/mL, p=0.47), while sputum anti-
CCP positive At-Risk and RA subjects also had similar levels of sputum cell counts (for total cells, 
68.9 vs. 74.1 cells x10
4
/mL, p=0.90; for macrophages, 25.3 vs. 20.3 cells x10
4
/mL, p=0.26; for 
neutrophils, 30.0 vs. 60.2 cells x10
4
/mL, p=0.58). 







































































1. All results are reported in median (IQR) in cells x104/mL 
2. P-value compares medial levels between groups using Kruskal Wallis test 
3. Sputum CCP positivity is defined as positivity for sputum anti-CCP3.1, anti-CCP-IgG and/or anti-CCP-IgA 
  28 
Chapter III conclusions. We identified a portion of At-Risk subjects (26%) and RA subjects 
(57%) with anti-CCP antibodies present in the sputum. Importantly, the majority of sputum anti-CCP 
positive At-Risk subjects demonstrated anti-CCP/total Ig ratios higher in sputum than serum and 
some serum anti-CCP negative At-Risk subjects demonstrated sputum anti-CCP positivity supporting 
that these anti-CCP antibodies were being generated in the lung in a modest portion of At-Risk 
subjects. We also found that sputum anti-CCP-IgA positivity was more prevalent in At-Risk subjects, 
whereas sputum anti-CCP-IgG positivity was more prevalent in RA subjects suggesting that sputum 
anti-CCP-IgA may play a larger role in the preclinical period of RA whereas sputum anti-CCP-IgG 
may play a larger role in transitions to classified RA. Finally, in At-Risk subjects, sputum anti-CCP 
antibodies were strongly associated sputum levels of neutrophils and macrophages supporting that 







LONGITUDINAL SPUTUM RHEUMATOID ARTHRITIS-RELATED ANTIBODIES  
 
Background and Review of the Literature 
 
Systemic ACPAs over time during preclinical RA. Serum studies provide insight into the 
ACPA changes that occur during the preclinical phase of RA development. Retrospective serum 
biobank studies demonstrate that ACPA increases in level and in the number of individual ACPA 
reactivities over time as the onset of clinically classifiable RA approaches (20, 21). After the onset of 
classified RA, serum ACPA remains stable in the majority of patients, even with immunosuppressive 
medications. However, the evolution of ACPA at a mucosal site such as the lung during preclinical or 
classified RA has not been studied. 
 
Sputum reproducibility over time. Induced sputum has been used in vaccination studies to 
monitor the immune response in the lung over time (87). Studies have also determined that repeated 
sputum testing over time is reproducible, although there can be slight variations within each person 
(88). Because sputum is easy to repeat over time from a safety and cost standpoint, it provides an 
opportunity to investigate changes in sputum ACPA over time in a large number of subjects.  
 
Methods and Analysis Plan 
 
Study design. This aim is a longitudinal observational cohort study. 
 
Subjects. From the 180 At-Risk, 70 RA and 140 Control subjects recruited in Chapter III, we 
randomly recruited subjects to participate in a longitudinal study visit that was at least 3 months after 
their baseline study visit. We had 51 At-Risk, 26 RA and 27 Controls complete at second study visit 
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with a longitudinal sputum sample collected. The median (range) of time in months between the 
baseline and longitudinal study visit was 16 (11-27) for At-Risk, 14 (12-22) for RA and 23 (16-31) 
for Controls. Of these subjects, 27 At-Risk and 12 RA subjects had sputum sample testing for anti-
CCP-IgA and anti-CCP-IgG on samples from both visits. 
 
Study visit. For each subject, the study visit from Chapter III was used as the baseline study 
visit. At the longitudinal study visit, subjects completed questionnaires to obtain any change in their 
medical history, medication usage, smoking history, self-reported history of pneumonia, acute 
bronchitis or chronic lung disease. Subjects also underwent a blood draw and an induced sputum 
collection. Subjects without RA underwent a follow-up 68-count joint examination performed by a 
study rheumatologist to evaluate for any development of incident inflammatory arthritis classifiable 
as RA.  
 
Induced sputum collection and ACPA testing. The same protocols were used for induced 
sputum collection and testing of CCP3.1, CCP-IgG and CCP-IgA as those described in Chapter III. 
The cut-off levels for sputum and serum anti-CCP3.1, anti-CCP-IgG and anti-CCP-IgA positivity that 
were established in Chapter III were also used to determine sputum and serum CCP3.1 positivity for 
At-Risk, RA and Control subjects in Chapter IV.  
 
Reproducibility of sputum ACPA testing. To determine the reproducibility of sputum 
ACPA testing, we recruited 10 RA subjects and 10 healthy Control subjects who underwent 2 
separate induced sputum collections separated by 4-7 days. The rationale for inclusion of these two 
groups was that the majority of RA subjects would be expected to have high sputum ACPA levels 
and the majority of Control subjects would be expected to have low sputum ACPA levels. The 
rationale for collecting samples 4-7 days apart was that during this short time period, it would be 
expected that a subjects’ generation of anti-CCP antibodies in the sputum would not substantially 
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change. Of the 20 subjects recruited, 7 RA subjects and 9 Control subjects had adequate samples for 
testing. All samples were tested for anti-CCP3.1 level, and we compared the sputum anti-CCP3.1 
levels between the 2 samples. The mean coefficient of variation between the 2 samples was 15.8% 
overall, and 14.1% in the 13 subjects who had not recently smoked any tobacco or non-tobacco 
products. 
  
Serum cohort of longitudinal anti-CCP-IgG and anti-CCP-IgA. In addition to the SERA 
subjects included in this Chapter, we also included a separate cohort of subjects to evaluate serum 
anti-CCP changes over time in a cohort of subjects who ultimately developed classified RA. This 
additional cohort is from the US Military’s Department of Defense (DoD) Serum Repository that is a 
repository of serum samples collected from members of the US Military at entry and various intervals 
during military service. From the DoD Serum Repository, we identified 125 individuals with 
classified RA confirmed by chart review and 210 Controls who did not develop RA and were 
matched to RA subjects based on age, sex, race, number of serum samples available, duration of 
sample storage and enlistment region. RA subjects had a serum sample after RA diagnosis as well as 
3 serum samples collected in the years prior to their RA diagnosis. Controls had 2-4 serum samples 
collected at similar intervals. All serum samples were tested for anti-CCP-IgA and anti-CCP-IgG as 
described above with the exception that, instead of using a positive control and calculating a relative 
unit based on the sample OD, for these DoD Serum Repository samples, we generated an in-house 
standard by pooling serum from 3 RA patients with high anti-CCP3.1 levels. Subsequently, serial 
dilutions were performed to generate a standard curve, and the results for anti-CCP isotypes in these 
DoD Serum Repository samples are reported in ELISA units.  
 
Analytic approach. To compare differences in the levels of anti-CCP in longitudinal 
samples, Wilcoxon matched pairs signed rank test was used. Because subjects differed in the length 
of time between their longitudinal visits, we used a general linear mixed model to assess the 
  32 
differences in sputum anti-CCP levels and sputum anti-CCP outcomes (positivity or negativity) 
between disease groups across time. Because of the non-normal distribution, the log transformed 
values of anti-CCP levels were used. The model included predictors of time between visits, subject 
group (i.e. At-Risk, RA or Controls), and the two-way interaction between time and subject group. 
Covariates (including age, gender, history of smoking, presence of the shared epitope allele, race, and 
history of chronic lung disease) were examined and removed from the model at an alpha ≥ 0.05. 




Subject characteristics compared to the overall cross-sectional group. When comparing 
baseline characteristics between the subset of subjects who were included in the longitudinal study of 
Aim 2 compared to the subjects from Aim 1 who were not included in Aim 2, there were no 
significant differences in age, sex, smoking history, presence of the shared epitope allele or history of 
chronic lung disease between At-Risk, RA or Control subjects who were included compared to those 
who were not included in Aim 2. For Controls, subjects included in Aim 2 were less likely to be non-
Hispanic white compared to those who did not participate in Aim 2 (54% vs. 83%, p<0.001), but this 
difference was not seen when comparing At-Risk or RA subjects who did or did not participate in the 
longitudinal study of Aim 2.  
 
Sputum anti-CCP3.1 levels over time in At-Risk, RA and Control subjects. When 
comparing anti-CCP3.1 levels at the baseline visit and the first longitudinal study visit, there was no 
significant change in the sputum anti-CCP3.1 level over time in At-Risk, RA or Control subjects 
(Figure 7). Using mixed models that account for differences in time between visits, there was no 
significant difference in sputum anti-CCP3.1 levels between groups over time (p=0.50). 
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Figure 7. Sputum anti-CCP3.1 levels over time. The figure depicts the level of sputum anti-CCP3.1 
at baseline study visit #1 and the first longitudinal study visit #2 in At-Risk (Panel A), RA (Panel B) 
and Controls (Panel C). P-values are calculated using Wilcoxon matched pairs signed rank test. Red 
dotted line represents the cut-off level for sputum anti-CCP3.1 positivity. 
 
Sputum anti-CCP3.1 positivity over time in At-Risk, RA and Control subjects. Overall, 
10/51 (19.6%) of At-Risk, 7/26 (26.9%) of RA and 1/27 (3.7%) of Controls had a change in sputum 
anti-CCP3.1 positivity, either newly gaining sputum anti-CCP3.1 positivity or losing a previous 
positivity for sputum anti-CCP3.1, and this net change in sputum anti-CCP3.1 positivity was more 
common in At-Risk and RA subjects compared to Controls (p=0.06) (Table 8). In addition, RA 
subjects were more likely to remain sputum anti-CCP3.1 positive (p<0.01), and Controls were more 
likely to remain sputum anti-CCP3.1 negative (p<0.01).  However, when using mixed models to 
account for time between visits, there was not a significant difference in the positivity, or negativity, 
of sputum anti-CCP3.1 over time between groups (p=0.45).  
 To explore factors associated with the development of incident anti-CCP3.1 positivity in 
sputum, we compared the following variables between subjects with incident sputum anti-CCP3.1 
positivity and those who remained sputum anti-CCP3.1 negative: median age, gender, race, ever-
smoking at baseline, current-smoking at follow-up visit, presence of the shared epitope allele, self-
reported history of chronic lung disease or pneumonia or bronchitis diagnosed by a health care 
provider in the past 1 year. In At-Risk subjects, there was a non-significant trend toward an 
association between incident sputum anti-CCP3.1 positivity and history of pneumonia in the past 
year. Specifically, 1/5 (20.0%) At-Risk subjects with a history of pneumonia in the past year had 
incident sputum anti-CCP3.1 positivity whereas 0/41 (0%) At-Risk subjects who remained sputum 
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p=0.98 p=0.59
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anti-CCP3.1 negative reported a history of pneumonia in the past year (20% vs. 0%, p=0.11). There 




Sputum anti-CCP-IgA and anti-CCP-IgG over time in At-Risk and RA In the 27 At-Risk 
subjects with anti-CCP-IgG and anti-CCP-IgA testing, incident sputum anti-CCP-IgG occurred in 
5/27 (18.5%), whereas incident sputum anti-CCP-IgA only occurred in 1/27 (3.7%) (Table 8). On 
average, At-Risk subjects had a decrease of 0.06 units [95% CI (-)0.021 – (-)0.09] in sputum anti-
CCP-IgA for every month between follow-up visits, when compared to RA subjects. In contrast, At-
Risk subjects had an increase of 0.09 units [95% CI (-)0.03 – 0.021] in sputum anti-CCP-IgG for 
every month between follow-up visits, when compared RA subjects. 
Table 8. Sputum anti-CCP3.1 changes in positivity over time 










   Incident positivity  0 (0) 5 (10) 3 (12) 0.17 
   Resolution of baseline positivity 1 (4) 5 (10) 4 (15) 0.32 
   Persistence of positivity 0 (0) 0 (0) 6 (23) <0.01 
   Persistence of negativity 26 (96) 41 (80) 13 (50) <0.01 
   Net change in positivity
2
 1 (4) 10 (20) 7 (27) 0.06 
Sputum CCP-IgA outcome, N (%)  (N=27) (N=12)  
   Incident positivity  - 1 (4) 1 (8) 0.53 
   Resolution of baseline positivity - 6 (22) 1 (8) 0.40 
   Persistence of positivity - 2 (7) 2 (17) 0.57 
   Persistence of negativity - 18 (67) 8 (67) 1.0 
   Net change in positivity
2
 - 7 (26) 2 (17) 0.69 
Sputum CCP-IgG outcome, N (%)  (N=27) (N=12)  
   Incident positivity  - 5 (19) 1 (8) 0.65 
   Resolution of baseline positivity - 0 (0) 0 (0)  1.0 
   Persistence of positivity - 1 (4) 4 (33) 0.02 
   Persistence of negativity - 21 (78) 7 (58) 0.26 
   Net change in positivity
2
 - 5 (19) 1 (8) 0.65 
1. P-value compares prevalence of the outcome within the entire group between all groups using 
Chi-square or Fisher’s exact test. 
2. Net change in positivity is defined as changing from negative to positive or changing from 
positive to negative. 
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In RA subjects, only 1/12 (8.3%) had incident sputum anti-CCP-IgG positivity and the same 
subject [1/12 (8.3%)] also had incident sputum anti-CCP-IgA positivity. RA subjects were 
significantly more likely than At-Risk subjects to have persistence sputum anti-CCP-IgG positivity 
[4/12 (33.3% vs. 1/27 (3.7%), p=0.03]. 
 
Serum anti-CCP changes over time. In At-Risk subjects, for anti-CCP3.1 positivity, 0/51 
(0%) had incident positivity, 1/51 (2.0%) had resolution of previously positivity, 19/51 (37.3%) 
stayed persistently positive and 31/51 (60.8%) stayed persistently negative. For serum anti-CCP-IgA, 
1/26 (3.8%) had incident positivity, 5/26 (19.2%) had resolution of previous positivity, 7/26 (26.9%) 
remained persistently positive and 13/26 (50.0%) remained persistently negative. For anti-CCP-IgG, 
0/26 (0%) had incident positivity, 7/26 (25.9%) had resolution of previous positivity, 9/26 (33.3%) 
remained persistently positive and 11/26 (40.7%) remained persistently negative. 
In RA subjects, for anti-CCP3.1 positivity, 0/26 (0%) had incident positivity, 3/26 (11.5%) 
had resolution of previous positivity, 23/26 (88.5%) stayed persistently positive and 0/26 (0%) stayed 
persistently negative. For serum anti-CCP-IgA, 1/12 (8.3%) had incident positivity, 0/12 (0%) had 
resolution of previously positivity, 5/12 (41.7%) stayed persistently positive and 6/12 (50.0%) stayed 
persistently negative. For serum anti-CCP-IgG, 0/26 (0%) had incident positivity, 0/26 (0%) had 
resolution of previously positivity, 11/12 (91.7%) stayed persistently positive and 1/12 (8.3%) stayed 
persistently negative. 
 
At-Risk subjects who converted to RA during follow-up. Four of the At-Risk subjects who 
were seen for a longitudinal study visit developed incident classified RA at their second study visit. 
One of the 4 (25%) was sputum anti-CCP3.1 negative at baseline and developed incident sputum anti-
CCP3.1 positivity at the longitudinal study visit. Three of the 4 (75%) were sputum anti-CCP3.1 
negative at baseline and remained sputum anti-CCP3.1 negative at their longitudinal study visit.  
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DoD serum repository longitudinal serum samples. As displayed in Figures 8 and 9, 
subjects who ultimately developed classified RA (blue circles in the Figures) demonstrated increasing 
levels of anti-CCP-IgG and anti-CCP-IgA up to the time point they developed classified RA (time 
point 0 along the x-axis). Of interest, in Control subjects who did not develop RA (red circles in the 
Figures), serum anti-CCP-IgG levels remained low over time, whereas serum anti-CCP-IgA levels in 
Controls fluctuated substantially over time.  
 
Figure 8. Serum anti-CCP-IgG levels over time. The figure depicts the mean regression line with 
standard deviations of the log-transformed level of serum anti-CCP-IgG (y-axis) in subjects who 
ultimately developed classified RA (blue circles) and Control subjects who did not develop RA (red 
circles). The x-axis displays days between serum samples with the time point ‘0’ being the day that 
































Figure 9. Serum anti-CCP-IgA levels over time. The figure depicts the mean regression line with 
standard deviations of the log-transformed level of serum anti-CCP-IgA (y-axis) in subjects who 
ultimately developed classified RA (blue circles) and Control subjects who did not develop RA (red 
circles). The x-axis displays days between serum samples with the time point ‘0’ being the day that 
RA subjects developed classified RA. Each circle represents an individual serum sample. 
 
Chapter IV conclusions. We identified several At-Risk subjects who developed incident 
sputum anti-CCP positivity over time. However, we also identified several At-Risk subjects who had 
resolution of sputum anti-CCP antibodies. There was a trend toward an association between recent 
pneumonia and incident sputum anti-CCP positivity suggesting that local inflammatory events in the 
lung may lead to anti-CCP generation, but larger studies are needed to confirm this hypothesis. In 
addition, in a large cohort of longitudinal serum samples, anti-CCP-IgA levels fluctuated substantially 
even in control subjects who did not develop RA. These findings suggest that transient elevations of 
anti-CCP-IgA may occur in many individuals that do not develop RA, and this may represent a 























ASSOCIATIONS OF ANTI-CCP AND ECTOPIC LYMPHOID TISSUE  
 
Background and Review of the Literature 
 
Bronchus associated lymphoid tissue (BALT).  BALT is defined as a well-organized 
aggregation of ectopic lymphoid tissue in the lung that includes primarily T and B lymphocytes, but 
also includes plasma cells, antigen-presenting follicular dendritic cells and high endothelial venules 
(89, 90). In humans and mice, BALT is not constitutively found in the lung (91), but it can be induced 
in a variety of inflammatory and infectious settings (92). As such, BALT in humans and mice is 
referred to as inducible BALT (iBALT). In fact, iBALT forms independent of secondary lymph 
organs supporting that iBALT forms directly as a result of local responses to infection or 
inflammation in the lung (90). iBALT has also been found to form early during infection and can 
remain for months after clearance of the infection (93, 94).  
  In addition, iBALT participates in priming antigen-specific T and B cell responses, 
lymphocyte proliferation and Ig class switching (90, 95). It often contains areas of active B cell 
proliferation in the form of germinal centers. iBALT can generate protective immunity locally in the 
lung, and while iBALT is well-organized by definition, less organized induced lymphoid aggregates 
can still be effective in generating local lung antibodies (90). Furthermore, iBALT can lead to faster, 
more efficient immune responses to respiratory infections and is therefore generally considered to be 
beneficial (96, 97). However, in some individuals, iBALT has been associated with lung tissue 
pathology, including more severe interstitial lung disease in RA patients (98).  
 
iBALT in RA. iBALT and less organized lymphoid aggregates have been identified in the 
lungs of patients with classified RA (98, 99). Even in early, untreated RA patients, a portion had 
iBALT-like structures identified in lung tissue (58). Of interest, iBALT in these early RA patients 
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was associated with ACPA and stained positively for citrullinated proteins. In addition to iBALT’s 
association with classified RA, lymphoid follicles similar to iBALT are present in a large number of 
preclinical RA patients who have serum ACPA positivity and chronic lung disease but do not have 
joint disease or classified RA (100). Moreover, disease specific autoantibodies being generated in 
ectopic lymphoid tissue, particularly in germinal centers, has also been describe in the salivary gland 
tissue of patients with Sjogren’s syndrome (101), and the presence of these tissue autoantibody 
producing cells was associated with systemic disease-specific autoantibodies. Similar studies are 
needed in RA to demonstrate that iBALT and antibody producing cells are present in the lung tissue 
in association with ACPA, even in the absence of classified RA.  
 
Methods and Analysis Plan 
 
Study design. This aim is a cross-sectional case-control observational study. 
 
Subjects. All subjects included in Chapter V were from the National Institute of Health 
(NIH)’s Lung Tissue Research Consortium (LTRC) that is a well-established human lung tissue 
repository that enrolls patients with a variety of lung diseases who are undergoing lung surgery for 
clinical purposes. The LTRC collects their surgical waste lung tissue, blood and extensive clinical 
data that are available to research investigators upon request.  
For this study, we included 10 subjects with RA and 61 subjects without RA who had lung 
tissue and blood available. The subjects without RA included 28 with interstitial lung disease (ILD) 
and 33 with emphysema. All diagnoses were made by clinical chart review and confirmed by tissue 
histology.  
 
ACPA testing. Serum from all subjects was tested for ACPA using the CCP ELISA assays 
described in Chapter III that included the commercial CCP3.1 assay (IgA/IgG, Inova Diagnostics Inc, 
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San Diego, CA, USA), and the CCP isotype specific CCP-IgG and CCP-IgA assays (Inova 
Diagnostics Inc, San Diego, CA, USA; for research only). As in Chapter III, anti-CCP3.1 was tested 
as per manufacturers instructions, and the cut-off level for positivity was that recommended by the 
manufacturer (≤20 ELISA units). For anti-CCP-IgG and anti-CCP-IgA, in this aim, we generated an 
in-house standard by pooling serum from 3 RA patients with high anti-CCP3.1 levels. Serial dilutions 
were performed to generate a standard curve, and the results for anti-CCP isotypes are reported in 
ELISA units. The cut-off levels for positivity of anti-CCP-IgG and anti-CCP-IgA were set at a level 
that was present in <2% of 126 healthy Control subjects corresponding to a level above the 98
th
 
percentile in these Controls.  
 
Lung tissue staining for iBALT. Lung tissue had been fixed in 10% formalin and embedded 
in paraffin per LTRC protocols. For this study, consecutive slides were stained with hematoxylin and 
eosin to determine the presence of lymphoid follicles and lymphoid follicles that were well-organized 
into germinal centers consistent with iBALT. All staining was performed by a technician who was 
blinded to the subjects’ RA or ACPA status. Stained slides were read by light microscopy and were 
interpreted by a single trained pathologist who was blinded to subjects’ RA or ACPA status. Slides 
were quantified for the presence and abundance of lymphoid follicles and germinal centers.  
 
Lung tissue staining for ACPA producing cells. In addition to routine staining, we 
performed additional immunohistochemical staining protocols to determine the presence of ACPA 
producing plasma cells. For these protocols, we included freshly cut lung tissue slides from 4 subjects 
identified by routine staining to have had at least 1 lymphoid follicle or germinal center present and 2 
subjects identified to have had no lymphoid follicles or germinal centers present. Slides were 
incubated with biotinylated citrullinated fibrinogen and citrullinated vimentin and fluorescence 
microscopy was preformed to identify binding of citrullinated antigen probes. 
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Analytic approach. We compared differences in the prevalence of ≥1 lymphoid follicle as 
well as the prevalence of ≥1 germinal center between RA subjects and non-RA controls using chi-
squared and Fishers exact testing, as appropriate. In RA and non-RA subjects, we evaluated 
associations between the presence of lymphoid follicles and germinal centers and the presence of 
serum anti-CCP positivity using chi-squared testing as well as with the level of serum anti-CCP using 
non-parametric Mann-Whitney U. We also performed logistic and linear regression models to 
evaluate these associations when accounting for covariates including age, sex, and smoking history. 




Subject characteristics. There was no significant difference in age, sex or smoking status 
between RA and non-RA subjects (Table 9). RA and non-RA ILD subjects were more often serum 
anti-CCP3.1 and anti-CCP-IgA positive and more often had germinal centers or lymphoid follicles 
present compared to non-RA emphysema subjects. 
 








Age, median (IQR) 56 (47-65) 60 (53-69) 67 (58-70) 0.10 
Female, N (%) 8 (80) 16 (50) 15 (54) 0.24 
Ever smoker, N (%) 7 (70) 23 (82) 24 (75) 0.59 
Current smoker, N (%) 1 (10) 1 (4) 3 (9) 0.56 
Serum CCP3.1 (+), N (%) 6 (60) 12 (43) 3 (9) <0.01 
Serum CCP-IgG (+), N (%) 6 (60) 2 (7) 2 (6) <0.01 
Serum CCP-IgA(+), N (%) 7 (70) 13 (46) 3 (9) <0.01 
Germinal center (+), N (%) 5 (50) 11 (39) 0 (0) <0.01 
Lymphoid follicle (+), N (%) 9 (90) 21 (75) 8 (25) <0.01 
 
Lymphoid follicle and germinal center associations with RA and anti-CCP. Overall, 
well-organized germinal centers were more prevalent in RA subjects compared to non-RA subjects 
(50.0% vs. 18.3%, p=0.04), but when considering non-RA subjects based on ILD vs. emphysema, the 
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presence of germinal centers was not different between RA and non-RA ILD subjects (50.0% vs. 
39.3%, p=0.71). Similar to the presence of germinal centers, lymphoid follicles were more prevalent 
in RA subjects compared to all non-RA subjects (90.0% vs. 48.3%, p=0.02), but the presence of 
lymphoid follicles was not significantly different between RA and non-RA ILD subjects (90.0% vs. 
75.0%, p=0.40). Examples of these structures are presented in Figure 10. 
 
Figure 10. Lung tissue histopathology based on H&E staining. The figure depicts representative 
images of a germinal center from a serum anti-CCP3.1/IgA/IgG positive RA subject (Panel A), a 
germinal center from a serum anti-CCP-IgA positive non-RA ILD subject (Panel B) and absence of 
germinal centers or lymphoid follicles in a non-RA emphysema subject (Panel C).  
  
When considering all subjects, serum anti-CCP3.1, anti-CCP-IgG and anti-CCP-IgA 
positivity was significantly associated with the presence of germinal centers on lung tissue histology 
(Table 10). Less well-organized lymphoid follicles were also associated with serum anti-CCP3.1 and 
anti-CCP-IgA positivity. In addition, when considering only non-RA subjects, serum anti-CCP-IgA 
was significantly associated with the presence of germinal centers as well as lymphoid follicles. 
Using logistic regression, these associations remained significant after adjusting for ever-smoking. 
Specifically, when adjusted for ever-smoking, in all subjects, the association of germinal centers 
remained significant for serum anti-CCP3.1 [OR=4.6 (95% CI 1.4-15.0], anti-CCP-IgG [OR=7.5 
(95% CI 1.8-31.6] and anti-CCP-IgA [OR=11.7 (95% CI 3.2-43.6]. Also, in non-RA subjects, when 
adjusted for ever-smoking, the association of germinal centers remained significant for anti-CCP-IgA 
[OR=8.0 (95% CI 1.9-33.8]. 
A.##RA#subject# B.##Non0RA#ILD#subject# C.#Non0RA#Emphysema#subject#
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Serum CCP3.1 (+) 9 (56) 12 (22) <0.01 16 (42) 5 (16) 0.02 
Serum CCP-IgG (+) 6 (38) 4 (7) <0.01 8 (21) 2 (6) 0.10 
Serum CCP-IgA (+) 12 (75) 11 (20) <0.01 19 (50) 4 (13) <0.01 
Non-RA Subjects 











Serum CCP3.1 (+) 5 (45) 10 (20) 0.12 10 (35) 5 (16) 0.14 
Serum CCP-IgG (+) 2 (18) 2 (4) 0.15 2 (7) 2 (7) 1.0 
Serum CCP-IgA (+) 7 (64) 9 (18) <0.01 12 (41) 4 (13) 0.02 
1.   All results are reported as number of subjects (%) 
 
Lung tissue staining for ACPA producing cells. We were unable to identify cells staining 
for citrullinated fibrinogen or citrullinated vimentin due to high background staining that was  




Figure 11. Lung tissue immunofluorescence staining for citrullinated fibrinogen. The figure 
depicts representative images of inadequate staining for citrullinated fibrinogen (red) and CD20+ B 
cells (green) in a serum anti-CCP3.1/IgA/IgG negative non-RA emphysema subject (Panel A) and a 








Chapter V conclusions. This study found a significant association between serum anti-CCP, 
particularly anti-CCP-IgA, and iBALT-like lymphoid follicles in the lung, even in subjects without 
RA. These findings support that the machinery required for local ACPA generation in the lung is 








CONCLUSION AND DISCUSSION 
 
Using induced sputum to measure ACPA levels in the lung, this project found that a portion 
of individuals who are At-Risk for RA (26%) and a portion of individuals with classified RA (57%) 
demonstrated anti-CCP antibodies in the lung. We also compared the ratio of anti-CCP/Ig in sputum 
and serum, which established that in the majority of At-Risk subjects, these anti-CCP antibodies were 
being generated in the lung and not translocated from the blood. This conclusion is further supported 
by the finding that some serum anti-CCP negative At-Risk subjects demonstrated sputum anti-CCP 
positivity in the lung in the absence of any anti-CCP antibodies in the blood. In aggregate, these data 
provide strong support for the conclusion that in a portion of individuals, anti-CCP generation 
appears to originate in the lung. However, we also found a portion of At-Risk and RA subjects who 
had serum ACPA positivity in the absence of any elevations of sputum ACPA. This finding suggests 
that the lung is unlikely the only mucosal site where ACPA is generated, and it is likely that other 
mucosal sites play a role in ACPA generation in some individuals At-Risk for RA and with classified 
RA. 
In addition, this project demonstrated that sputum anti-CCP antibodies were strongly 
associated with markers of airway inflammation, including elevated sputum levels of neutrophils and 
macrophages. These data support that anti-CCP antibodies are not randomly present in the sputum of 
these subjects, but are instead associated with evidence of local airway inflammation. It also supports 
that ACPA in the sputum could be generated through local immune interactions and inflammation in 
the airways, although, it is also possible that anti-CCP antibodies in the lung target lung tissue that 
leads to subsequent inflammation. 
Importantly, sputum anti-CCP antibodies in this project were most strongly associated with 
classified RA supporting their relevance to RA pathogenesis. It was of particular interest, that sputum 
anti-CCP-IgG was more strongly associated with classified RA, whereas sputum anti-CCP-IgA was 
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more prevalent in At-Risk subjects. This is in line with serum studies that have identified stronger 
associations between classified RA and ACPA-IgG compared to a higher prevalence of ACPA-IgA in 
individuals At-Risk for RA (41, 42). The combination of these sputum and serum findings strongly 
suggest that anti-CCP-IgG antibodies are more relevant to joint inflammation in RA, whereas anti-
CCP-IgA antibodies may be a more mucosal-relevant early antibody isotype generated in the 
preclinical period of RA. Longer longitudinal studies are needed, but these findings raise an 
interesting hypothesis that the development of anti-CCP-IgG may be the critical step that leads to the 
transition from systemic autoimmunity to inflammatory arthritis in the development of RA. 
We also found that sputum anti-CCP positivity was higher in At-Risk subjects who were 
serum anti-CCP positive compared to serum anti-CCP negative At-Risk subjects. This finding is 
meaningful because it is likely that serum anti-CCP positive subjects are further along in the 
developmental phases of RA development (79). In fact, a large portion of serum anti-CCP negative 
At-Risk subjects who only have a familial risk of RA will never develop serum ACPA or classified 
RA (77, 78). This group is still critical to study in order to understand the earliest steps in the 
generation of ACPA because they are enriched for developing RA over the general population, but it 
is not unexpected that the prevalence of sputum anti-CCP positivity would be lower in these 
individuals. 
Strengths of these sputum studies include the large number of subjects studied, the unique 
population studied and the utilization of commonly used methodologies (i.e. induced sputum 
collection) to test an uncommonly studied outcome (i.e. anti-CCP antibodies in the lung). Regarding 
our unique population, arthritis-free subjects At-Risk for future RA can be difficult to identify as they 
do not often present to clinical settings. Our project overcame that issue by recruiting At-Risk 
subjects who had already participated in RA research through the established SERA cohort. 
Furthermore, the use of sputum samples to test for ACPA in the lung, which are cheap and safe, made 
it possible to recruit a large number of subjects as well as to enroll a moderate percentage of those 
subjects in longitudinal studies. The convenience of sputum is also important if findings from future 
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studies that develop out of this project are able to identify a biomarker that can be used in clinical or 
other research settings. 
While the use of sputum is a strength, it is also associated with several limitations. For 
example, sputum passes through the oral cavity and can be contaminated by saliva. Our sputum 
collection protocols include measures to minimize this issue, and we have performed comparative 
studies testing anti-CCP in sputum and saliva that showed that anti-CCP detected in sputum is not 
from a salivary source (82). Another limitation is that our Control group was younger than our At-
Risk and RA subjects. Since we did not identify an association between age and ACPA level, this 
difference is unlikely to significantly impact our results, but future studies are needed to ensure that in 
a larger group of older healthy controls, anti-CCP levels are not elevated in the sputum. In addition, 
the majority of our RA subjects were on immunosuppressing medications that could impact 
inflammation and antibody production. Although, in prior studies we have not seen a difference in 
sputum anti-CCP positivity between RA subjects who were or were not immunosuppressed (82). 
The longitudinal study of this project found that while several At-Risk subjects developed 
incident sputum anti-CCP positivity over time, several also had resolution of previously identified 
sputum anti-CCP antibodies. This finding along with our findings in serum from a separate cohort 
suggest that while anti-CCP-IgA is still strongly associated with classified RA, transient elevations 
can occur in many individuals that is perhaps part of natural autoantibody response that occurs in 
many individuals. Other autoantibody systems have identified natural IgA autoantibodies that do not 
appear to have the same pathogenic effects as IgG autoantibodies (102). It may even be that IgA 
autoantibodies serve a protective role against mucosal pathogens. Because of these sputum antibody 
fluctuations within individuals, our longitudinal findings clearly demonstrate that a much larger 
number of subjects will need to be followed over a longer period of time to fully understand the 
patterns of evolution of sputum anti-CCP antibodies. However, these data are a critical first step to 
understanding the prevalence of this phenomenon. While it is possible that methodologic issues 
related to sputum collection could result in some of the antibody level fluctuations (e.g. sputum anti-
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CCP3.1 coefficient of variation = 15% in reproducibility studies), the magnitude of the antibody level 
changes demonstrated were above the variation of sputum collection in the majority of subjects.  
Furthermore, using a unique resource of lung tissue samples, this project was able to 
demonstrate that the machinery required for local antibody generation in the lung, specifically ectopic 
lymphoid follicles and germinal centers consistent with iBALT, was present in association with anti-
CCP antibodies. In particular, serum anti-CCP-IgA antibodies in subjects without RA were strongly 
associated with the presence of germinal centers and lymphoid follicles in the lung. In this study, we 
were not able to specifically demonstrate ACPA producing plasma cells in the lung tissue of RA or 
preclinical RA subjects, which was likely the result of protein degradation during tissue processing 
protocols. In addition, because we only evaluated a single section of the lung, sampling errors could 
result in having missed iBALT structures in other areas of the lung.  However, this effect would be 
possible in all subjects and would likely affect all groups equally. Although we did not have paired 
sputum samples in these subjects, these data provide important insight for mechanisms by which anti-
CCP antibodies could be generated in the lung and subsequently identified in the sputum.  
This project is important to the clinical care of patients with RA, because it provides novel 
insight into how autoimmunity in RA may originate, and it could ultimately lead to novel prevention 
strategies in RA that target a specific mucosal site at the initial site of immune dysregulation. This 
project also provides additional support to change the paradigm of our understanding of the etiology 
of RA such that it is increasingly clear that autoimmunity in RA is initially triggered at a site outside 
of the lungs. These studies provide the groundwork for future studies that can identify a sputum 
biomarker(s) that more specifically predict At-Risk individuals who later develop classified RA, and 
such sputum biomarkers could be used clinically to determine RA risk. It is more likely that the 
findings in this project will have a direct impact on future research studies that investigate the 
etiology of systemic autoimmune diseases. Several potential future studies specific to RA are 
described in Chapter VI, but this project highlights a model of autoantibody development that could 
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FUTURE RESEARCH DIRECTIONS 
 
The findings in this project advance our understanding of where ACPA may originate, and set 
the groundwork for several important future areas of research. Important next questions include what 
mechanisms lead to the mucosal generation of ACPA. In particular, what environmental factors 
interacting in the lung can stimulate the generation of ACPA, and are particular genetic risk alleles 
involved? It is important to consider that based on our findings and the findings of others, anti-CCP-
IgG appears to be more strongly associated with classified RA compared to anti-CCP-IgA that was 
more prevalent in At-Risk subjects. Therefore, the mechanisms driving the generation of ACPA may 
change over time during the different phases of RA development. Along these lines, two specific lines 
of investigation that are of particular interest in ACPA and RA development are that of neutrophil 
extracellular traps (NETs) and microbiota.  
NET formation (termed NETosis) is a process during which activated neutrophils release 
their chromatin in complex with intracellular proteins (103-105). This process commonly occurs in 
response to inflammation or bacteria. Of importance in RA and ACPA generation, NETosis can 
externalize citrullinate proteins as well as PAD enzymes that can citrullinate nearby proteins (106-
108). Also, neutrophils from RA patients demonstrate increased rates of NETosis compared to 
controls and are associated with serum ACPA (107). Increased NET formation has also been 
described in sputum in patients with chronic lung disease (109), and our group has previously 
identified that increased levels of NET remnants correlated with increased levels of anti-CCP 
antibodies in the sputum of subjects At-Risk for RA (82). However, future studies are needed to 
investigate whether NETosis in the lung is a mechanism leading to the initial generation of ACPA or 
if NETosis in the lung is instead the result of a separate factor that led to ACPA generation (e.g. 
microbiota). Areas of study that can begin to address this question will include evaluating whether 
there is an inherent difference in the neutrophils of At-Risk subjects that predisposes them to 
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increased rates of NETosis, and whether the association of NETosis and ACPA is related to the 
specific citrullinated proteins bound to the chromatin of NETs induced in At-Risk subjects. In 
addition, NETotic debris is cleared by macrophages, and it will also be important to study whether 
dysfunctional macrophage clearance in At-Risk subjects may also contribute to abnormal levels of 
NETosis in the lung.  
Regarding microbiota as a potential mechanism that could trigger ACPA in the lung, studies 
have long suggested that RA may be triggered by a bacterium (110-113). More recent studies have 
identified associations between RA and specific bacteria including Prevotella copri and 
Porphyromonas gingivalis (114, 115). There are several potential mechanisms that have been 
suggested by which bacteria could trigger ACPA. For example, some bacteria, including 
Porphyromonas gingivalis, possess a bacterial PAD enzyme that could citrullinate local proteins 
(114, 116, 117), bacteria could contain proteins that cross-react with human proteins resulting in 
molecular mimicry as occurs with Streptococcus pyogenes and rheumatic fever (118), bacteria at 
mucosal surfaces could adversely influence the development of the innate and adaptive immune 
systems (119, 120) or bacteria could lead to generalized inflammation that could activate nearby 
autoreactive cells through bystander activation (121). Each of these possibilities should be explored in 
relation to mucosal ACPA generation. However, an important first step would be to determine 
whether certain bacteria in the sputum are associated with local ACPA generation. 
Another mechanism of interest is that of the citrullinated proteins in the lung. It is known that 
smoking and lung inflammation can lead to higher levels of citrullinated proteins in the lung (61, 62), 
and an important question related to ACPA in the lung is whether a generalized increase in the total 
number of citrullinated proteins is associated with ACPA or whether it is specific citrullinated 
proteins in the lung that are relevant to ACPA generation. Using induced sputum, our group did not 
identify a generalized increase in citrullinated proteins associated with ACPA in the lung, but 
additional studies are needed (82).  
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In addition to mechanistic studies, future studies will also include continued longitudinal 
follow-up of At-Risk subjects in order to better understand patterns of mucosal ACPA evolution. 
Such longitudinal studies will also be able to identify what additional factors (e.g. smoking, 
microbiota, or cytokines) contribute to the persistence of sputum ACPA or contribute to the transition 
from mucosal to systemic ACPA and ultimately classified RA. Furthermore, based on our 
conclusions that lung may be one of several mucosal sites involved in the generation of ACPA, it will 
be critical to evaluate additional mucosal sites in At-Risk subjects. In pilot studies, we have begun to 
investigate the female genital tract as a potential mucosal site of ACPA generation that is specific to 
women and may inform the etiology of the higher prevalence of RA in women, particularly younger 
women (1). Preliminary results from these studies suggest that similar to the lung, a portion of women 
At-Risk for RA demonstrate generation of ACPA in the female genital tract mucosa. Finally, it will 
be important to simultaneously study multiple mucosal sites within a single At-Risk individual to 
determine whether it is a single mucosal site or a combination of mucosal sites where autoimmunity 
is being generated in the preclinical period of RA. 
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